Eric C. Jeschke
128 IP cases indexed. Covers patent matters.
Cases Presided Over
128 cases indexed | Page 2 of 5
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable, finding anticipation and obviousness over Schaffer and its combinations with Hartley, Eller, and Garrison.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s U.S. Patent 12,016,580 covering intravascular embolism treatment devices after finding Imperative Care’s obviousness arguments sufficiently promising.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted institution of an IPR against Inari Medical’s 12,016,580 hemostasis valve patent, finding a reasonable likelihood that Imperative Care will prevail on at least one of the nine challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s likelihood of success sufficient. All nine claims are now under trial.
Kubota North America Corporation et al. v.Vermeer Manufacturing Company
Kubota North America Corporation successfully petitioned PGR against Vermeer Manufacturing Company's patent for agricultural machinery, leading to institution on all 11 challenged claims. The Board found sufficient evidence of anticipation and obviousness based on prior art references like KR996.
Kubota North America Corporation et al. v.Vermeer Manufacturing Company
Kubota North America Corporation successfully petitioned the PTAB against Vermeer Manufacturing Company's patent, leading to institution on all 10 challenged claims. The Board adopted Petitioner's interpretation of 'loader support,' finding that prior art supports anticipation and obviousness grounds.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis valve patent are unpatentable, finding anticipation and obviousness over Schaffer and combinations with Hartley, Eller, and Garrison.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success. The review will cover claims 1‑9 and is based on anticipation and obviousness grounds over Schaffer, Hartley, and Eller references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care secured institution of an IPR against Inari Medical’s hemostasis‑valve patent covering claims 1‑9. The Board found a reasonable likelihood of unpatentability based on anticipation and obviousness over Schaffer and related references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB denied Imperative Care's petition to institute an IPR against Inari Medical's embolism‑treatment patent, finding no reasonable likelihood of success on any of the 31 challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB institution decision in this IPR found that the petitioner met its burden of showing a reasonable likelihood of prevailing on at least claim 1. The dispute centers on obviousness (35 U.S.C. § 103) regarding medical devices used for aspirating clot material from blood vessels.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
In an IPR, the PTAB held that all nine claims of Inari Medical’s hemostasis valve patent are unpatentable under §§102 and 103, finding the petitioner’s anticipation and obviousness arguments persuasive.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB denied Imperative Care’s petition to review Inari Medical’s 11,744,691 patent covering catheter‑based embolism removal. The Board found the petitioner had not shown a reasonable likelihood of prevailing on any of the 31 challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care secured institution of an IPR against Inari Medical’s hemostasis‑valve patent, covering claims 1‑9, on grounds of anticipation and obviousness.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,011 hemostasis valve patent after Imperative Care demonstrated a reasonable likelihood of unpatentability on claims 1‑9.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 patent covering a vacuum aspiration system with hemostasis valve. Petitioner Imperative Care showed a reasonable likelihood of prevailing on at least one claim, especially claim 1, based on obviousness over Garrison, Schaffer and other references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care successfully met the institution burden in its IPR against Inari Medical's '333 patent, establishing a reasonable likelihood of prevailing on key claims. The Board found that combining prior art references like Laub and Garrison renders the claimed thromboembolism treatment systems obvious under 103.
Generac Power Systems, Inc. et al. v.Champion Power Equipment, Inc.
Generac Power Systems successfully convinced the PTAB to institute IPR proceedings against Champion Power Equipment, Inc., regarding a dual-fuel generator control system. The Board found sufficient showing of obviousness and anticipation across multiple grounds using prior art references like DuroMax and De Vries.
Straumann USA, LLC et al. v.Smart Denture Conversions, LLC.
Straumann USA, LLC successfully petitioned against Smart Denture Conversions, LLC's patent, leading to institution of IPR proceedings. The Board found a reasonable likelihood that claims are unpatentable under both anticipation (102) and obviousness (103).
Harbor Freight Tools USA, Inc. et al. v.Champion Power Equipment, Inc.
The PTAB institution decision found a reasonable likelihood of unpatentability for the multi-fuel generator patent (10393034). The Board adopted Petitioner's claim construction regarding 'gaseous fuel,' which was critical to establishing obviousness and anticipation grounds.
SIG Sauer Inc. v.True Velocity, Inc.
SIG SAUER and True Velocity settled their IPR dispute over patent 8,561,543, leading the Board to dismiss the proceeding before trial.
Straumann USA, LLC et al. v.Smart Denture Conversions, LLC.
Straumann USA successfully petitioned for institution in a Post-Grant Review challenging Smart Denture Conversions' dental implant patent (12156781). The Board found likelihood of unpatentability based on indefiniteness and lack of written description/enablement. This sets a precedent regarding the sufficiency of disclosure in complex medical device claims.
AROMA 360, LLC v.Air Esscentials, Inc.
AROMA 360 successfully petitioned the PTAB against Air Esscentials' patent (10092918) regarding aerosol/fluid dispersion technology. The Board instituted the IPR, finding a reasonable likelihood of prevailing on obviousness grounds over Goubet and Gao-2 prior art references.
AROMA 360, LLC v.Air Esscentials, Inc.
AROMA 360, LLC successfully petitioned to challenge claims of Air Esscentials, Inc.'s patent (10583449) before the PTAB. The Board found a reasonable likelihood of prevailing on multiple grounds, leading to institution of the IPR.
AROMA 360, LLC v.Air Esscentials, Inc.
AROMA 360, LLC successfully petitioned the PTAB to institute IPR against Air Esscentials, Inc.'s patent (9527094) for obviousness. The Board found a reasonable likelihood of prevailing regarding claim 7 based on Sevy, leading to trial institution.
Decent Espresso International Ltd. v.DUVALL ESPRESSO IP ENFORCEMENT, LLC
The PTAB denied institution of an IPR for a beverage brewing system patent (11957271), finding that the petitioner failed to show a reasonable likelihood of prevailing. The denial hinged on the Board's determination that key prior art, Buttiker, was not applicable.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,012 patent covering hemostasis valves after finding Imperative Care’s petition shows a reasonable likelihood of success on at least one claim.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted inter partes review on all 15 claims of Inari Medical’s embolism‑treatment patent after finding Imperative Care’s obviousness arguments sufficiently persuasive.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s ’291 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success. All 16 challenged claims are now under review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s likelihood of success on at least one claim. All nine claims are now under review.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.